scholarly journals Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations

2018 ◽  
Vol 5 (4) ◽  
pp. 361-372 ◽  
Author(s):  
Tiago A. Mestre ◽  
Monica Busse ◽  
Aileen M. Davis ◽  
Lori Quinn ◽  
Filipe B. Rodrigues ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Functional Ability ◽  
Rating Scales ◽  
And Performance

Rating scales for cognition in Huntington's disease: Critique and recommendations

2017 ◽  
Vol 33 (2) ◽  
pp. 187-195 ◽  
Author(s):  
Tiago A. Mestre ◽  
Anne-Catherine Bachoud-Lévi ◽  
Johan Marinus ◽  
Julie C. Stout ◽  
Jane S. Paulsen ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales

scholarly journals An Automated Home-Cage System to Assess Learning and Performance of a Skilled Motor Task in a Mouse Model of Huntington’s Disease

eNeuro ◽  
2017 ◽  
Vol 4 (5) ◽  
pp. ENEURO.0141-17.2017 ◽  
Author(s):  
Cameron L. Woodard ◽  
Federico Bolaños ◽  
James D. Boyd ◽  
Gergely Silasi ◽  
Timothy H. Murphy ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Home Cage ◽  
Motor Task ◽  
Cage System ◽  
And Performance ◽  
Learning And Performance

Response to letter by Saenz‐Farret et al. on “Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations”

2017 ◽  
Vol 32 (3) ◽  
pp. 482-482
Author(s):  
Tiago A. Mestre ◽  
Erik van Duijn ◽  
Aileen M. Davis ◽  
Anne‐Catherine Bachoud‐Lévi ◽  
Monica Busse ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales ◽  
Behavioral Symptoms

scholarly journals Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations

2018 ◽  
Vol 5 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Tiago A. Mestre ◽  
Maria João Forjaz ◽  
Philipp Mahlknecht ◽  
Francisco Cardoso ◽  
Joaquim J. Ferreira ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales ◽  
Motor Symptoms ◽  
Symptoms And Signs

Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales

2020 ◽  
Vol 60 (8) ◽  
pp. 1051-1060
Author(s):  
Wan Sun ◽  
Di Zhou ◽  
John H. Warner ◽  
Douglas R. Langbehn ◽  
Guenther Hochhaus ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Disease Progression ◽  
Rating Scales ◽  
Population Modeling ◽  
Modeling Approach ◽  
Clinical Rating

Validation of self-report depression rating scales in Huntington's disease

2009 ◽  
Vol 25 (1) ◽  
pp. 91-96 ◽  
Author(s):  
Jennifer De Souza ◽  
Lisa A. Jones ◽  
Hugh Rickards
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales ◽  
Self Report

scholarly journals Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations

2016 ◽  
Vol 31 (10) ◽  
pp. 1466-1478 ◽  
Author(s):  
Tiago A. Mestre ◽  
Erik van Duijn ◽  
Aileen M. Davis ◽  
Anne-Catherine Bachoud-Lévi ◽  
Monica Busse ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales ◽  
Behavioral Symptoms

The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in Huntington’s Disease

2020 ◽  
Vol 9 (3) ◽  
pp. 291-302
Author(s):  
David Isaacs ◽  
Jessie S. Gibson ◽  
Jeffrey Stovall ◽  
Daniel O. Claassen
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Discriminant Validity ◽  
Rating Scales ◽  
Rating Scale ◽  
Psychiatric Symptoms ◽  
Self Report ◽  
Depression And Anxiety ◽  
Patient Reported ◽  
The Impact

Background: Psychiatric symptoms are widely prevalent in Huntington’s disease (HD) and exert greater impact on quality of life than motor manifestations. Despite this, psychiatric symptoms are frequently underrecognized and undertreated. Lack of awareness, or anosognosia, has been observed at all stages of HD and may contribute to diminished patient self-reporting of psychiatric symptoms. Objective: We sought to evaluate the impact of anosognosia on performance of commonly used clinical rating scales for psychiatric manifestations of HD. Methods: We recruited 50 HD patients to undergo a formal psychiatrist evaluation, the Problem Behavior Assessment-Short Form (PBA-s), and validated self-report rating scales for depression, anxiety, and anger. Motor impairment, cognitive function, and total functional capacity were assessed as part of clinical exam. Patient awareness of motor, cognitive, emotional, and functional capacities was quantified using the Anosognosia Rating Scale. Convergent validity, discriminant validity, classification accuracy, and anosognosia effect was determined for each psychiatric symptom rating scale. Results: Anosognosia was identified in one-third of patients, and these patients underrated the severity of depression and anxiety when completing self-report instruments. Anosognosia did not clearly influence self-reported anger, but this result may have been confounded by the sub-optimal discriminant validity of anger rating scales. Conclusion: Anosognosia undermines reliability of self-reported depression and anxiety in HD. Self-report rating scales for depression and anxiety may have a role in screening, but results must be corroborated by provider and caregiver input when anosognosia is present. HD clinical trials utilizing patient-reported outcomes as study endpoints should routinely evaluate participants for anosognosia.

Tolerability and efficacy of the monoaminergic stabilizer (−)-OSU6162 (PNU-96391A) in Huntington’s disease: a double-blind cross-over study

2014 ◽  
Vol 26 (5) ◽  
pp. 298-306 ◽  
Author(s):  
Angelica Kloberg ◽  
Radu Constantinescu ◽  
Marie Karin Lena Nilsson ◽  
Maria Lizzie Carlsson ◽  
Arvid Carlsson ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Rating Scales ◽  
Short Form ◽  
Primary Objective ◽  
Double Blind ◽  
Good Tolerability ◽  
Motor Functions ◽  
Clinical Investigator ◽  
The Individual

ObjectiveTo evaluate the safety (primary objective) and efficacy (secondary objective) of (−)-OSU6162 in Huntington’s disease (HD).MethodsIn a double-blind, cross-over trial, patients with HD were randomly assigned to start treatment on either (−)-OSU6162 or placebo. After 4 weeks, those patients who initially received active drug were switched to placebo for another 4 weeks, and vice versa. During the first week the (−)-OSU6162 dose was 15 mg twice daily, during the second week 30 mg twice daily, and during the last 2 weeks 45 mg twice daily. Motor, cognitive, mental and social functions were rated by the clinical investigator or by self-assessment, using established rating scales.ResultsFifteen patients fulfilling inclusion and exclusion criteria completed the study. (−)-OSU6162 was well tolerated by all patients and no adverse effects were observed. (−)-OSU6162 treatment significantly improved the Short Form 36 Vitality score, mainly due to an improvement of the individual item ‘worn-out’ (VT3). In addition, an improvement of depressive symptoms was found using Beck Depression Inventory. In contrast to a general trend of improvement in several non-motor variables only small and non-significant differences between (−)-OSU6162 and placebo were found regarding motor functions.Conclusions(−)-OSU6162 offers promise for the treatment of HD, as a drug with good tolerability, capable of improving the patients’ experienced non-motor functions such as energy and mood and thus alleviating symptoms of great importance for their quality of life.

Sign in / Sign up

Export Citation Format

Share Document